Which long-term antiplatelet regimen for patients with acute coronary syndromes?

Andrea Picchi, Marco Ferlini, Ugo Limbruno, Stefano de Servi

Research output: Contribution to journalArticle

Abstract

Dual antiplatelet therapy (DAPT ) is recommended up to 12 months in patients with acute coronary syndromes, but the risk of cardiovascular events in this group of subjects remains high, also in the long-term follow-up. The potential benefit of a prolonged period of DAPT has recently been assessed in three large-volume randomized clinical trials (PEGASUS, DAPT-MI, TRA2P-TIMI 50) but final results are quite difficult to interpret and clear indications for the clinical practice are so far lacking. A direct comparison of the three studies is challenging since relevant differences exist as to clinical features and risk profile of the study populations. Different anti-platelet drugs have been tested in addition to aspirin making it difficult to understand which antithrombotic regimen guarantees the best balance between thrombotic and haemorragic events. Finally, specific designs of these trials, evaluating complex composite end-points, may generate further difficulties in the interpretation of data. We believe that the use of total mortality rather than cardiovascular death as end-point, would better describe the long-term outcome incorporating the catastrophic consequences of bleeding. This review seeks to highlight strengths and weaknesses of these three large-volume trials and tries to establish whether or not prolonging DAPT beyond 12 months in patients with acute coronary syndromes is useful and which anti-thrombotic regimen would offer the best balance between thrombotic and bleeding risk.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalCardiovascular Drugs and Therapy
DOIs
Publication statusAccepted/In press - May 18 2016

Fingerprint

Acute Coronary Syndrome
Hemorrhage
Therapeutics
Aspirin
Blood Platelets
Randomized Controlled Trials
Mortality
Pharmaceutical Preparations
Population

Keywords

  • Acute coronary syndrome
  • Antiplatelet therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Which long-term antiplatelet regimen for patients with acute coronary syndromes? / Picchi, Andrea; Ferlini, Marco; Limbruno, Ugo; de Servi, Stefano.

In: Cardiovascular Drugs and Therapy, 18.05.2016, p. 1-6.

Research output: Contribution to journalArticle

@article{65c520d3fe3a42a7b506fd571c17569e,
title = "Which long-term antiplatelet regimen for patients with acute coronary syndromes?",
abstract = "Dual antiplatelet therapy (DAPT ) is recommended up to 12 months in patients with acute coronary syndromes, but the risk of cardiovascular events in this group of subjects remains high, also in the long-term follow-up. The potential benefit of a prolonged period of DAPT has recently been assessed in three large-volume randomized clinical trials (PEGASUS, DAPT-MI, TRA2P-TIMI 50) but final results are quite difficult to interpret and clear indications for the clinical practice are so far lacking. A direct comparison of the three studies is challenging since relevant differences exist as to clinical features and risk profile of the study populations. Different anti-platelet drugs have been tested in addition to aspirin making it difficult to understand which antithrombotic regimen guarantees the best balance between thrombotic and haemorragic events. Finally, specific designs of these trials, evaluating complex composite end-points, may generate further difficulties in the interpretation of data. We believe that the use of total mortality rather than cardiovascular death as end-point, would better describe the long-term outcome incorporating the catastrophic consequences of bleeding. This review seeks to highlight strengths and weaknesses of these three large-volume trials and tries to establish whether or not prolonging DAPT beyond 12 months in patients with acute coronary syndromes is useful and which anti-thrombotic regimen would offer the best balance between thrombotic and bleeding risk.",
keywords = "Acute coronary syndrome, Antiplatelet therapy",
author = "Andrea Picchi and Marco Ferlini and Ugo Limbruno and {de Servi}, Stefano",
year = "2016",
month = "5",
day = "18",
doi = "10.1007/s10557-016-6667-0",
language = "English",
pages = "1--6",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - Which long-term antiplatelet regimen for patients with acute coronary syndromes?

AU - Picchi, Andrea

AU - Ferlini, Marco

AU - Limbruno, Ugo

AU - de Servi, Stefano

PY - 2016/5/18

Y1 - 2016/5/18

N2 - Dual antiplatelet therapy (DAPT ) is recommended up to 12 months in patients with acute coronary syndromes, but the risk of cardiovascular events in this group of subjects remains high, also in the long-term follow-up. The potential benefit of a prolonged period of DAPT has recently been assessed in three large-volume randomized clinical trials (PEGASUS, DAPT-MI, TRA2P-TIMI 50) but final results are quite difficult to interpret and clear indications for the clinical practice are so far lacking. A direct comparison of the three studies is challenging since relevant differences exist as to clinical features and risk profile of the study populations. Different anti-platelet drugs have been tested in addition to aspirin making it difficult to understand which antithrombotic regimen guarantees the best balance between thrombotic and haemorragic events. Finally, specific designs of these trials, evaluating complex composite end-points, may generate further difficulties in the interpretation of data. We believe that the use of total mortality rather than cardiovascular death as end-point, would better describe the long-term outcome incorporating the catastrophic consequences of bleeding. This review seeks to highlight strengths and weaknesses of these three large-volume trials and tries to establish whether or not prolonging DAPT beyond 12 months in patients with acute coronary syndromes is useful and which anti-thrombotic regimen would offer the best balance between thrombotic and bleeding risk.

AB - Dual antiplatelet therapy (DAPT ) is recommended up to 12 months in patients with acute coronary syndromes, but the risk of cardiovascular events in this group of subjects remains high, also in the long-term follow-up. The potential benefit of a prolonged period of DAPT has recently been assessed in three large-volume randomized clinical trials (PEGASUS, DAPT-MI, TRA2P-TIMI 50) but final results are quite difficult to interpret and clear indications for the clinical practice are so far lacking. A direct comparison of the three studies is challenging since relevant differences exist as to clinical features and risk profile of the study populations. Different anti-platelet drugs have been tested in addition to aspirin making it difficult to understand which antithrombotic regimen guarantees the best balance between thrombotic and haemorragic events. Finally, specific designs of these trials, evaluating complex composite end-points, may generate further difficulties in the interpretation of data. We believe that the use of total mortality rather than cardiovascular death as end-point, would better describe the long-term outcome incorporating the catastrophic consequences of bleeding. This review seeks to highlight strengths and weaknesses of these three large-volume trials and tries to establish whether or not prolonging DAPT beyond 12 months in patients with acute coronary syndromes is useful and which anti-thrombotic regimen would offer the best balance between thrombotic and bleeding risk.

KW - Acute coronary syndrome

KW - Antiplatelet therapy

UR - http://www.scopus.com/inward/record.url?scp=84969786964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969786964&partnerID=8YFLogxK

U2 - 10.1007/s10557-016-6667-0

DO - 10.1007/s10557-016-6667-0

M3 - Article

AN - SCOPUS:84969786964

SP - 1

EP - 6

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

ER -